These results support the therapeutic hypothesis of enhancing TREM2 activity as a novel approach for efficacious interventions for Alzheimer's disease, and potentially other neurodegenerative diseases as well as metabolic disorders associated with obesity. Here, TREM2 is linked to obesity due to melanocortin 4 receptor deficiency.